BR112014011137A2 - polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento - Google Patents

polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento

Info

Publication number
BR112014011137A2
BR112014011137A2 BR112014011137A BR112014011137A BR112014011137A2 BR 112014011137 A2 BR112014011137 A2 BR 112014011137A2 BR 112014011137 A BR112014011137 A BR 112014011137A BR 112014011137 A BR112014011137 A BR 112014011137A BR 112014011137 A2 BR112014011137 A2 BR 112014011137A2
Authority
BR
Brazil
Prior art keywords
polypeptide
making
polynucleotide
antibody
drug
Prior art date
Application number
BR112014011137A
Other languages
English (en)
Inventor
Hofmann Fred
Groer Gerthard
Frevert Jürgen
Schmidt Michael
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48288558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011137(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BR112014011137A2 publication Critical patent/BR112014011137A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014011137A 2011-11-09 2012-11-08 polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento BR112014011137A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161628911P 2011-11-09 2011-11-09
EP11188440 2011-11-09
US201261659137P 2012-06-13 2012-06-13
EP12171801 2012-06-13
PCT/EP2012/072158 WO2013068476A1 (en) 2011-11-09 2012-11-08 Neurotoxins exhibiting shortened biological activity

Publications (1)

Publication Number Publication Date
BR112014011137A2 true BR112014011137A2 (pt) 2018-06-12

Family

ID=48288558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011137A BR112014011137A2 (pt) 2011-11-09 2012-11-08 polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento

Country Status (18)

Country Link
US (1) US9809809B2 (pt)
EP (1) EP2776457B1 (pt)
JP (1) JP6162135B2 (pt)
KR (1) KR20150000468A (pt)
CN (1) CN103974973A (pt)
AR (1) AR089655A1 (pt)
AU (1) AU2012334080B2 (pt)
BR (1) BR112014011137A2 (pt)
CA (1) CA2855173A1 (pt)
CL (1) CL2014001217A1 (pt)
ES (1) ES2638333T3 (pt)
HK (1) HK1199890A1 (pt)
IL (1) IL232508B (pt)
MX (1) MX351012B (pt)
RU (1) RU2646110C2 (pt)
SG (1) SG11201402131TA (pt)
TW (1) TWI583792B (pt)
WO (1) WO2013068476A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091895A1 (en) * 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
KR102083371B1 (ko) 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
EP3154635A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154571A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
JP6772138B2 (ja) * 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
KR102557798B1 (ko) 2014-12-23 2023-07-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
EP3242884B1 (en) * 2015-01-09 2021-02-24 Ipsen Bioinnovation Limited Cationic neurotoxins
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
US11969461B2 (en) 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
CN106432423B (zh) * 2016-09-21 2019-05-10 北京大学深圳研究生院 一种α-螺旋多肽及其用途
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
KR20190126894A (ko) * 2017-03-22 2019-11-12 본티, 인크. 치료법에서 사용하기 위한 보툴리눔 신경독소
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) * 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
WO2019133179A2 (en) * 2017-12-01 2019-07-04 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
CN117964751A (zh) * 2018-03-13 2024-05-03 斯米维特公司 与破伤风神经毒素结合的单域抗体
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CN109666683B (zh) * 2019-02-27 2021-10-29 昆明理工大学 乙酰辅酶A乙酰转移酶基因RKAcaT2及其应用
CN110721314B (zh) * 2019-10-11 2022-11-29 江苏恒泰生物科技有限公司 一种抗肿瘤纳米药物及其制备方法
SE2050326A1 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
CN111763663B (zh) * 2020-07-09 2022-04-15 昆明理工大学 一种天麻葡糖基转移酶基因及应用
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333609A (en) * 1996-07-05 2000-08-25 Cancer Res Campaign Tech Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
GB9708089D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP2266600B1 (en) 2004-07-26 2014-09-10 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
WO2008106507A2 (en) * 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
EP2134749B1 (en) * 2007-03-22 2013-11-06 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
FR2924721B1 (fr) 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
US8343743B2 (en) * 2008-06-10 2013-01-01 Synaptic Research, Llc Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain
CN102471765B9 (zh) * 2009-07-02 2016-07-27 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素

Also Published As

Publication number Publication date
US9809809B2 (en) 2017-11-07
RU2014123060A (ru) 2015-12-20
JP6162135B2 (ja) 2017-07-12
TW201326390A (zh) 2013-07-01
SG11201402131TA (en) 2014-08-28
KR20150000468A (ko) 2015-01-02
EP2776457A1 (en) 2014-09-17
WO2013068476A1 (en) 2013-05-16
MX2014005544A (es) 2014-05-30
AU2012334080B2 (en) 2016-12-15
EP2776457B1 (en) 2017-08-02
TWI583792B (zh) 2017-05-21
MX351012B (es) 2017-09-28
AR089655A1 (es) 2014-09-10
JP2014533945A (ja) 2014-12-18
CN103974973A (zh) 2014-08-06
CA2855173A1 (en) 2013-05-16
RU2646110C2 (ru) 2018-03-01
AU2012334080A1 (en) 2014-05-15
IL232508B (en) 2018-06-28
HK1199890A1 (en) 2015-07-24
CL2014001217A1 (es) 2014-10-10
ES2638333T3 (es) 2017-10-19
US20140308267A1 (en) 2014-10-16
IL232508A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
BR112014011137A2 (pt) polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
CL2013003031A1 (es) Metodo para estratificacion a base de bcma en pacientes con mieloma multiple; anticuerpo anti-bcma.
BR112014028024A2 (pt) método para processar um material de biomassa.
DK2714735T3 (da) Antistoffer, der er specifikke for TGF-beta
DK3448034T3 (da) Fremgangsmåde til at udlede bevægelsesinformation
EP2770794A4 (en) ACCESS PROCEDURE FOR A WIFI ACCESS POINT, WIFI ACCESS POINT AND WIFI SYSTEM
BR112014001855A2 (pt) construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
BR112014003798A2 (pt) método para fabricar um composto, e, composto
BR112015002536A2 (pt) métodos para produzir recipientes flexíveis.
BR112013022559A2 (pt) cartão, e, método para fabricar um cartão
BR112014003566A2 (pt) célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico
BR112014008603A2 (pt) tablete, e, método para produzir um tablete
DK3829172T3 (da) Fremgangsmåde til at konstruere fletningsliste
DK2758172T3 (da) System til udførelse af reaktioner
BR112014003444A2 (pt) célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico
DK2573571T3 (da) Sporbarhed til automatiseret farvningssystem
BR112013030423A2 (pt) método para produção de biocoque
BR112013030846A2 (pt) vetor de expressão, célula hospedeira não humana, método para a fabricação de uma proteína e uso de um vetor de expressão
GB201403292D0 (en) Information search system, method and program
BR112013019036A2 (pt) célula hospedeira recombinante, e, método para produzir um ácido dicarboxílico.
EP2765521A4 (en) SEARCH SYSTEM, OPERATING PROCESS FOR SEARCH SYSTEM AND PROGRAM
BR112013030695A2 (pt) método para o processamento de um sistema multifásico
DK2602216T3 (da) Logistiksystem, overføringsstation til dette, samt logistikfremgangsmåde
BR112014012534A2 (pt) métodos para a preparação de hidrogéis
BR112014001859A2 (pt) sistema baculoviral para a expressão de um vetor de terapia gênica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2539 DE 03-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]